GSK plc
Pfizer RSV vaccine for older adults is only slightly less effective after 18 months
Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images Pfizer‘s vaccine that protects adults ages 60 and older from respiratory syncytial virus was slightly less effective after 18 months, according to clinical trial results the company announced Wednesday. The data is from New York-based Pfizer’s clinical trial on more than […]
Read More
Musk’s Neuralink valued at about $5 billion even with extended road to marketplace: Reuters
Jonathan Raa | Nurphoto | Getty Images Elon Musk’s mind implant startup Neuralink, which was valued at near to $2 billion in a private fundraising spherical two a long time in the past, is now value all around $5 billion dependent on privately executed inventory trades described to Reuters by 5 sources with understanding of […]
Read More
FDA approves Pfizer RSV vaccine for older adults
Luis Alvarez | Digitalvision | Getty Images The Food and Drug Administration on Wednesday approved a vaccine made by Pfizer that protects adults ages 60 and older from respiratory syncytial virus, a common pathogen that kills and hospitalizes thousands of seniors every year. Pfizer, in a statement Wednesday, said it expects to have supply available […]
Read More
FDA advisors recommend Pfizer’s RSV vaccine for infants but raise safety concerns
Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images The Food and Drug Administration’s independent panel of advisors on Thursday recommended full approval of Pfizer’s vaccine that protects infants from RSV, but raised safety concerns over premature births that may be tied to the shot. The committee unanimously said the […]
Read More
Pfizer RSV vaccine for infants has ‘generally favorable’ safety data, FDA staff say
Blood sample for respiratory syncytial virus (RSV) test Jarun011 | Istock | Getty Images U.S. Food and Drug Administration staff on Tuesday said Pfizer’s vaccine that protects infants from respiratory syncytial virus has “generally favorable” safety data. The FDA staff made the conclusion in briefing documents ahead of a meeting on Thursday, when a panel […]
Read More
FDA approves GSK’s RSV vaccine for older adults, world’s first shot against virus
A GSK lab in London. Oli Scarff | Getty Images The Food and Drug Administration on Wednesday approved an RSV vaccine produced by GlaxoSmithKline for use on adults ages 60 and older. The approval, the first ever globally by a regulatory body for an RSV vaccine, is a decisive victory for GSK in a race […]
Read More
This worldwide professional genuine-estate stock is set to increase by 60%, Jefferies states
Jefferies expects shares of U.K.-targeted commercial authentic-estate stock Life Science REIT to rise by far more than 60% over the upcoming 12 months. The expense bank’s prediction arrives at a time when the world wide professional true estate market place has found price ranges drop sharply above the previous 12 months . In the U.K., […]
Read More
The EU outlined its program to equalize drug obtain and lessen costs. Pharma companies are not happy
A molecular biologist examines wastewater samples for pathogens in the basic safety laboratory at the Max Delbrück Heart for Molecular Medicine in Mitte. Photo Alliance | Image Alliance | Getty Illustrations or photos The European Union on Wednesday introduced its prolonged-awaited overhaul of present pharmaceutical laws, reflecting the bloc’s most significant shake-up of rules governing […]
Read More
Stocks making the biggest moves midday: Southwest Airlines, Goldman Sachs, Bellus Health and more
In this article LMT NVDA GS JNJ LUV Follow your favorite stocksCREATE FREE ACCOUNT The Lockheed Martin logo is seen on a building in Annapolis Junction, Maryland, on March 11, 2019. Jim Watson | AFP | Getty Images Check out the companies making headlines in midday trading. Lockheed Martin – Shares of the aerospace and […]
Read More
J&J backs out of RSV vaccine race with rivals Pfizer and GSK
A Johnson & Johnson building is shown in Irvine, California. Mike Blake | Reuters Johnson & Johnson on Wednesday said it’s ducking out of the RSV vaccine race, weeks after competitors Pfizer and GSK inched closer to launching the world’s first shot against the deadly virus. J&J will stop working on its investigational RSV adult […]
Read More